Versiro develops software that accelerates the energy transition. Renewable electricity is great for the environment but difficult to plan because its production depends on uncertain weather conditions. Versiro develops an AI copilot that helps renewable producers make smart decisions in real time while considering these uncertainties. This assists the integration of renewable energy and increases its profitability, two key factors to enable the green energy transition. Versiro was founded by researchers at the Norwegian University of Science and Technology (NTNU) and follows the observation that, in electric power systems, the traditional pipelines from research to industry are too outdated to keep up with the fast-paced world of machine learning.

What is Between? The process of moving out of your home and into a new one can be one of the greatest stresses of life. To the average person, it’s an expensive and overwhelming process that involves listmaking, phone calls with real estate agents, taking time off from work, packing, heavy lifting, buying takeaway dinners, cleaning, and so on. Have you ever wondered why there’s no app that could help alleviate the pain points of moving? We have. That’s why we founded Between – Norway’s first moving platform. Between is a digital service that revolutionizes the moving process with technology, innovation and the ability to understand needs. To the average person, it means less stress and more control. To electrical and insurance companies, who each year lose thousands of customers due to address changes, it will lead to a lower churn rate and a higher return on investment. To real estate agents and developers, we will provide added value to a much smoother customer journey. What we have achieved We are a small group of entrepreneurs who have founded several successful businesses together. One of which is an online change of address service, a pilot company which has helped us research the moving market for the last two years – with over 50.000 registered customers in Norway and Sweden. Between is the next step. Not just for us, but for the millions of people out there who are about to begin a new life in a new home. We’re doing this because we know that if we can make moving easier, we will also make life easier.

UpStacked is the All-in-One centralized operations platform that crushes SLA requirements to increase profitability and reduce OPEX. Purpose-built for internal IT and MSPs to operate SMBs and Enterprises. With user experience in mind, UpStacked drives complex to zero-touch, through automation and machine learning. UpStacked at a Glance: - All-in-One Centralized Platform - Enterprise onboarding in minutes - Third-Party integrations - Zero-Touch - Simplified License Management - Real-Time On-Demand Reporting - Real-Time Topology Based Correlation - Real-Time Event-Based Correlation - Built-in Role Based Access Control - Natively Multi-Tenant - Multi-Vendor - ITIL

Get your products from the manufacturer to the end customer in the fastest and easiest way possible. Regardless of existing volume or size - NBS provides you with the sales channels, systems, and logistics to reach the whole of Norway. IT-system One system for product registration, sales, statistics, and inventory for your products. Fully integrated with all the services you need. Logistics Efficient logistics from a central warehouse in Vestby of 5,500 m2 specially built for handling beverages. Sales to all channels Sell ​​your products under 4.7% alcohol to private customers through Lokalbrygg.no, over 4.7% alcohol to Vinmonopolet, and everything to HoReCa through horecalevering.no. Marketing and Fairs Increase your visibility through our own fairs for HoReCa, private customers, and Vinmonopolet.

Moderne Media ble startet med et ønske om å formidle gode historier. Det er fortsatt kjerneverdien i alt vi gjør. Med podkast, TV, film, reklame og sosiale medier, har vi flere muligheter enn noen gang til å produsere og dele gode historier.Folkene du møter i Moderne Media jobber med det de synes er morsomst, og det de er flinkest til. Vi har oppdaget at de to tingene har en sammenheng. Derfor prøver vi å rendyrke personligheter og individer.

Vi bistår våre kunder med markedsstrategier både digitalt og analogt. Zebra Media er et nytenkende og kreativt mediebyrå som har spesialisert seg på strategier, kreativt design og innovativ markedsteknologi. Zebra Media er et medie- og reklamebyrå med fokus på å hjelpe bedrifter å finne de rette løsningene innen digital markedsføring og grafisk design.

Speak Norsk is an ambitious team that started with one goal in mind – to make expats fluent in Norwegian! We are passionate about language-learning and bringing to Norway a new, innovative way of teaching Norwegian. Since the beginning, we have been known for our interactive conversation-focused classes, own-written books, and something that it´s not quite common for other schools – a personal approach and a customized offer for each one of our students. Meet our passionate and united team of Speak Norsk school!

Movel AS provides support and invoicing services for AC charging systems. We specialize in systems that provide normal charging for long-term and overnight parking. Movel wants to contribute to a more environmentally friendly life. Therefore, all power in Movel's charging systems provides renewable energy.

EpiGuard AS is an innovative Norwegian Medical Technology Company established in 2015 by a group of doctors at the Oslo University Hospital (OUS) together with co-founders Inven2, Eker Group AS, and Hansen Protection AS. EpiGuard has evolved into a highly skilled knowledge-based company. The business model is to develop and manufacture high-end medical equipment for the safe transport of contagious patients. The products will be distributed globally through strategic partners. Currently, the main product is the medical isolation and transportation system, EpiShuttle. The system is developed by clinical experts at OUS, with first-hand experience in providing advanced treatment and transportation of patients with highly infectious diseases, such as Ebola.

Otivio’s main product, FlowOx™, is addressing chronic wounds with focus on peripheral arterial disease (PAD), which is a serious condition leading to pain, chronic wounds and in many cases amputation and mortality. The patient population is very large and increasing. There are limited adequate treatment options offered to the patients aside from surgical interventions. FlowOx™ is a non-invasive product intended for home use. Long-term patient testing in more than 50 patients documents increased blood flow, reduced pain and wound healing. FlowOx™ is CE marked. In fourth quarter 2017 had its commercial break-through through sales of FlowOx to public customers.

"Safe Cycling AS" is focused on providing cycling race organizers with mobile warning signs, giving them a great opportunity to develop and increase the quality of the competition. Our product and service will take the race safety to next level. A mobile warning sign is a revolution in cycling and is a big step forward in safety procedure development and up-growth.

Oncoinvent AS is a privately held Norwegian company established in 2010. The company is committed to developing new innovative products to provide better treatment options to cancer patients. The innovations being developed by Oncoinvent AS are a result of the extensive experience with the development of radionuclide-based cancer treatments of two of the founders, Dr. Roy H. Larsen and Professor of clinical oncology Øyvind S. Bruland. Larsen and Bruland are the inventors of the first FDA and EMA-approved alpha-emitting pharmaceutical product Xofigo® (Bayer AG), as well as of the beta-emitting radio-immunotherapeutic product candidate Betalutin® (Nordic Nanovector ASA). Oncoinvent's lead product candidate, Radspherin®, is a novel alpha-emitting radioactive microsphere designed for the treatment of metastatic cancers in body cavities. Radspherin® has been shown to cause a significant reduction in tumor cell growth. It is anticipated that the product can potentially treat several forms of metastatic cancer. The first clinical indication for Radspherin® will be the treatment of peritoneal carcinomatosis. Clinical development will be conducted in collaboration with European and American clinical research centers.

Biozep is discovering and developing first-in-class drug products for the treatment of severe eye diseases which can lead to vision loss and where it is a high unmet medical need. Biozep has discovered novel drug substances based on bioactive lipids which modulate central pathways involved in the pathogenesis of eye diseases. Targets and biomarkers are identified based on a system biology approach combined with in-depth knowledge about bioactive lipids, their endogenous synthesis and mechanisms of action. Biozep has made a prototype drug product based on our lead compound for topical administration and the product will be tested in animal models in 2018. Our goal is to start clinical studies in 2020. Biozep is a company depending on both internal and external resources. Biozep has established its own laboratory in Oslo in order to do synthesis, purification, quality control and chemical development in-house. The biological testing of the drug substances is performed in collaboration with carefully selected contract research organizations both in Europe and the USA. In order to reach the market as fast as possible and to reduce risk, Biozep will seek strategic partnerships early in the drug development phase. Biozep seeks partners with complementary competence and with resources to conduct clinical trials and with market access. We are already in dialogue with potential partners and hope to sign an agreement in 2018-19.

Medsensio will develop educational, clinical, and monitoring tools by analyzing medical data using machine learning and statistics. Our first project is developing an auscultation learning tool for students. Students will be able to verify their own interpretations of lung sounds using our machine-learning technology

An intracellular approach to diagnostics – changing the way diagnostics approach blood tests. Pre Diagnostics is the first diagnostics company to focus on intracellular measurements of disease-specific biomarkers inside the blood cells. We extract disease-relevant information from biomarkers located inside specific blood cells called monocytes to provide actionable results for patients and practitioners.